{
  "nct_id": "NCT10000001",
  "title": "Targeted Therapy in HER2+ Breast Cancer",
  "summary": "Phase 3 randomized study evaluating targeted therapy plus standard of care in adults with HER2-positive breast cancer.",
  "status": "RECRUITING",
  "phase": "PHASE3",
  "conditions": ["Breast Cancer", "HER2 Positive Breast Cancer"],
  "locations": [
    "New York, New York, United States",
    "Boston, Massachusetts, United States"
  ],
  "fetched_at": "2026-02-10T14:00:00Z",
  "eligibility_text": "Inclusion Criteria:\nParticipants must be 18 years or older.\nHistologically confirmed HER2-positive breast cancer.\nECOG performance status 0 to 1.\nAdequate organ function documented within 14 days.\nLVEF >= 50% by echocardiogram.\nNo prior progression on study backbone drugs.\nAble to comply with study visits.\n\nExclusion Criteria:\nPregnant or breastfeeding.\nKnown active CNS metastases requiring steroids.\nUncontrolled hypertension.\nRecent myocardial infarction within 6 months.\nCurrent severe infection.\nHistory of hypersensitivity to investigational product.\nConcurrent enrollment in conflicting interventional trial.\nUse of prohibited medications within washout period.\nQTc > 480 ms.\nAny condition that, in investigator judgment, increases risk.\n\nAdditional Notes:\nParticipants will complete patient-reported outcomes every cycle.\nArchived tissue samples should be submitted when available.\nParticipants should use effective contraception during treatment and 6 months after final dose.",
  "criteria_parser_version": "m5-v1",
  "coverage_stats": {
    "total_rules": 5,
    "known_rules": 5,
    "unknown_rules": 0,
    "failed_rules": 0,
    "coverage_ratio": 1.0
  },
  "criteria": [
    {
      "id": "rule-inc-age",
      "type": "INCLUSION",
      "field": "age",
      "operator": ">=",
      "value": 18,
      "unit": "years",
      "certainty": "high",
      "evidence_text": "Participants must be 18 years or older."
    },
    {
      "id": "rule-inc-condition",
      "type": "INCLUSION",
      "field": "condition",
      "operator": "IN",
      "value": "HER2-positive breast cancer",
      "unit": null,
      "certainty": "high",
      "evidence_text": "Histologically confirmed HER2-positive breast cancer."
    },
    {
      "id": "rule-inc-lab",
      "type": "INCLUSION",
      "field": "lab",
      "operator": ">=",
      "value": 50,
      "unit": "%",
      "certainty": "medium",
      "evidence_text": "LVEF >= 50% by echocardiogram."
    },
    {
      "id": "rule-exc-history",
      "type": "EXCLUSION",
      "field": "history",
      "operator": "WITHIN_LAST",
      "value": 6,
      "unit": "months",
      "certainty": "high",
      "evidence_text": "Recent myocardial infarction within 6 months."
    },
    {
      "id": "rule-exc-other",
      "type": "EXCLUSION",
      "field": "other",
      "operator": "EXISTS",
      "value": "active severe infection",
      "unit": null,
      "certainty": "medium",
      "evidence_text": "Current severe infection."
    }
  ]
}
